Avidity Biosciences, Inc. (Nasdaq: RNA) has announced that it will present findings from its Phase 1/2 FORTITUDE™ trial at the 32nd Annual FSHD Society International Research Congress, scheduled for June 12-13, 2025, in Amsterdam, the Netherlands. The company will deliver two oral and one poster presentations. The trial evaluates delpacibart braxlosiran (del-brax), an Antibody Oligonucleotide Conjugate (AOC™), in adults with facioscapulohumeral muscular dystrophy (FSHD). Jeffrey M. Statland, M.D., of the University of Kansas Medical Center, will present the topline data from the dose escalation cohorts A and B on June 13, 2025. Additionally, Stephen Tapscott, M.D., Ph.D., of the Fred Hutchinson Cancer Center, will discuss a novel DUX4-regulated circulating biomarker in both oral and poster formats on June 12, 2025. The presentations and poster are accessible on Avidity's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.